Interpace Biosciences, Inc. Announces Board Changes
January 28, 2020 at 04:11 pm EST
Share
On January 22, 2020, the board of directors of Interpace Biosciences, Inc. appointed and elected Fortunato Ron Rocca as a Class II director. Mr. Rocca is the President and Chief Executive Officer of Exagen Inc. Mr. Rocca will serve until the company's 2021 annual meeting of stockholders, until his respective successor is elected and qualified, or until his earlier death, resignation or removal. Mr. Rocca will serve on the Board as a non-employee director. Mr. Rocca was designated by 1315 Capital II, L.P. ("1315 Capital") as a holder of the Company's Series B Convertible Preferred Stock. The Board has determined that Mr. Rocca qualifies as an "independent director" under the rules of the Nasdaq Stock Market LLC. Mr. Rocca was named to the Audit Committee and Compensation & Management Development Committee of the Board. Concurrently with Mr. Rocca's appointment and election as a Class II Director, Dr. Felice Schnoll-Sussman resigned from the Board as well as all applicable committees thereof, including the Audit Committee, Compensation & Management Development Committee, and Nominating and Corporate Governance Committee, in each case effective as of January 22, 2020.
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.